RIPK1 in necroptosis and recent progress in related pharmaceutics
Necroptosis is a programmed form of cell death. Receptor-interacting serine/threonine protein kinase l (RIPK1) is a crucial protein kinase that regulates the necroptosis pathway. Increased expression of death receptor family ligands such as tumor necrosis factor (TNF) increases the susceptibility of...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1480027/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823859430696943616 |
|---|---|
| author | Kunhou Yao Zhihao Shi Fengya Zhao Cong Tan Yixin Zhang Hao Fan Yingzhe Wang Xingwang Li Jun Kong Qun Wang Dingxi Li |
| author_facet | Kunhou Yao Zhihao Shi Fengya Zhao Cong Tan Yixin Zhang Hao Fan Yingzhe Wang Xingwang Li Jun Kong Qun Wang Dingxi Li |
| author_sort | Kunhou Yao |
| collection | DOAJ |
| description | Necroptosis is a programmed form of cell death. Receptor-interacting serine/threonine protein kinase l (RIPK1) is a crucial protein kinase that regulates the necroptosis pathway. Increased expression of death receptor family ligands such as tumor necrosis factor (TNF) increases the susceptibility of cells to apoptosis and necroptosis. RIPK1, RIPK3, and mixed-lineage kinase-like domain (MLKL) proteins mediate necrosis. RIPK1-mediated necroptosis further promotes cell death and inflammation in the pathogenesis of liver injury, skin diseases, and neurodegenerative diseases. The N-terminal kinase domain of RIPK1 is significant in the induction of cell death and can be used as a vital drug target for inhibitors. In this paper, we outline the pathways of necroptosis and the role RIPK1 plays in them and suggest that targeting RIPK1 in therapy may help to inhibit multiple cell death pathways. |
| format | Article |
| id | doaj-art-d8f265dbd1044b529c4460932c6889db |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-d8f265dbd1044b529c4460932c6889db2025-02-11T05:10:24ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.14800271480027RIPK1 in necroptosis and recent progress in related pharmaceuticsKunhou Yao0Zhihao Shi1Fengya Zhao2Cong Tan3Yixin Zhang4Hao Fan5Yingzhe Wang6Xingwang Li7Jun Kong8Qun Wang9Dingxi Li10Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, ChinaSchool of Basic Medicine, Henan University, Kaifeng, ChinaSchool of Basic Medicine, Henan University, Kaifeng, ChinaSchool of Basic Medicine, Henan University, Kaifeng, ChinaSchool of Basic Medicine, Henan University, Kaifeng, ChinaSchool of Basic Medicine, Henan University, Kaifeng, ChinaSchool of Basic Medicine, Henan University, Kaifeng, ChinaDepartment of General Surgery, Huaihe Hospital of Henan University, Kaifeng, ChinaSchool of Basic Medicine, Henan University, Kaifeng, ChinaSchool of Basic Medicine, Henan University, Kaifeng, ChinaDepartment of Gynaecology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaNecroptosis is a programmed form of cell death. Receptor-interacting serine/threonine protein kinase l (RIPK1) is a crucial protein kinase that regulates the necroptosis pathway. Increased expression of death receptor family ligands such as tumor necrosis factor (TNF) increases the susceptibility of cells to apoptosis and necroptosis. RIPK1, RIPK3, and mixed-lineage kinase-like domain (MLKL) proteins mediate necrosis. RIPK1-mediated necroptosis further promotes cell death and inflammation in the pathogenesis of liver injury, skin diseases, and neurodegenerative diseases. The N-terminal kinase domain of RIPK1 is significant in the induction of cell death and can be used as a vital drug target for inhibitors. In this paper, we outline the pathways of necroptosis and the role RIPK1 plays in them and suggest that targeting RIPK1 in therapy may help to inhibit multiple cell death pathways.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1480027/fullRIPK1necroptosisprogrammed cell deathinflammationkinase domainpharmaceutics |
| spellingShingle | Kunhou Yao Zhihao Shi Fengya Zhao Cong Tan Yixin Zhang Hao Fan Yingzhe Wang Xingwang Li Jun Kong Qun Wang Dingxi Li RIPK1 in necroptosis and recent progress in related pharmaceutics Frontiers in Immunology RIPK1 necroptosis programmed cell death inflammation kinase domain pharmaceutics |
| title | RIPK1 in necroptosis and recent progress in related pharmaceutics |
| title_full | RIPK1 in necroptosis and recent progress in related pharmaceutics |
| title_fullStr | RIPK1 in necroptosis and recent progress in related pharmaceutics |
| title_full_unstemmed | RIPK1 in necroptosis and recent progress in related pharmaceutics |
| title_short | RIPK1 in necroptosis and recent progress in related pharmaceutics |
| title_sort | ripk1 in necroptosis and recent progress in related pharmaceutics |
| topic | RIPK1 necroptosis programmed cell death inflammation kinase domain pharmaceutics |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1480027/full |
| work_keys_str_mv | AT kunhouyao ripk1innecroptosisandrecentprogressinrelatedpharmaceutics AT zhihaoshi ripk1innecroptosisandrecentprogressinrelatedpharmaceutics AT fengyazhao ripk1innecroptosisandrecentprogressinrelatedpharmaceutics AT congtan ripk1innecroptosisandrecentprogressinrelatedpharmaceutics AT yixinzhang ripk1innecroptosisandrecentprogressinrelatedpharmaceutics AT haofan ripk1innecroptosisandrecentprogressinrelatedpharmaceutics AT yingzhewang ripk1innecroptosisandrecentprogressinrelatedpharmaceutics AT xingwangli ripk1innecroptosisandrecentprogressinrelatedpharmaceutics AT junkong ripk1innecroptosisandrecentprogressinrelatedpharmaceutics AT qunwang ripk1innecroptosisandrecentprogressinrelatedpharmaceutics AT dingxili ripk1innecroptosisandrecentprogressinrelatedpharmaceutics |